Educational paper. The development of new therapies for pediatric oncology

Area of Science:

• Pediatric Oncology
• Molecular Therapeutics
• Drug Development

Background:

• Current cure rates for childhood cancers have plateaued around 70%, necessitating new therapeutic strategies.
• Difficult-to-treat pediatric malignancies like stage IV neuroblastoma, sarcomas, brain tumors, and relapsed leukemia require novel drug approaches.
• Existing treatments are insufficient for improving outcomes in high-risk or recurrent pediatric cancers.

Purpose of the Study:

• To provide an overview of novel molecular agents for pediatric cancers.
• To discuss agents at various stages of regulatory approval (FDA/EMA).
• To highlight drugs approved for children, adults, and those in early clinical or preclinical development.

Main Methods:

• Review of molecular agents targeting pediatric malignancies.
• Categorization of agents based on their approval status and stage of development.
• Inclusion of specific examples like cell cycle inhibitors, tyrosine kinase inhibitors, DNA binding compounds, and monoclonal antibodies.

Main Results:

• Several novel agents show promise for improving outcomes in high-risk or recurrent pediatric cancers.
• Cell cycle inhibitors (clofarabine, nelarabine) demonstrate efficacy in high-risk leukemia.
• Targeted agents including tyrosine kinase inhibitors, trabectedin, and monoclonal antibodies (GD2 inhibitors, anti-CD22 antibodies) show potential.

Conclusions:

• Novel molecular agents represent a critical advancement in treating challenging pediatric cancers.
• Targeted therapies and cell cycle inhibitors offer new avenues for improving cure rates in pediatric oncology.
• The development and approval of these agents are vital for addressing unmet needs in pediatric cancer treatment.